Álex Bataller

机构：The University of Texas MD Anderson Cancer Center, Universidad de Málaga · ORCID：0000-0002-6085-2745

发表论文 253 篇 · 总被引 1434 次 · h-index 21

代表论文

• Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia (2026 · Cancer)
• CLL-1265: Pirtobrutinib, Venetoclax, and Obinutuzumab Treatment in First-Line CLL (PIVOT-CLL) (2026 · Clinical Lymphoma Myeloma & Leukemia)
• POSTER: ALL-866: Three-Year Follow-Up of Dose-Dense Mini-CVD in Combination With Inotuzumab Ozogamicin and Blinatumomab for Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2026 · Clinical Lymphoma Myeloma & Leukemia)
• AML-460: Long-Term Follow-Up of Oral Decitabine/Cedazuridine (ASTX727) Plus Venetoclax in Older or Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia (2026 · Clinical Lymphoma Myeloma & Leukemia)
• POSTER: CLL-1265: Pirtobrutinib, Venetoclax, and Obinutuzumab Treatment in First-Line CLL (PIVOT-CLL) (2026 · Clinical Lymphoma Myeloma & Leukemia)
• ALL-866: Three-Year Follow-Up of Dose-Dense Mini-CVD in Combination With Inotuzumab Ozogamicin and Blinatumomab for Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2026 · Clinical Lymphoma Myeloma & Leukemia)